Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
The insider still has significant holdings in the company, signaling confidence.
Alkermes' Chief Commercial Officer sold 7,576 shares of the company's stock on August 17, 2026, according to a recent SEC filing. The transaction, valued at $373,000 based on the weighted average sale price of $49.23 per share, saw Nichols part with a substantial portion of his holdings. Nichols, the vice president and chief commercial officer, holds a significant position within Alkermes, a Dublin-based biopharmaceutical company with a market capitalization of $7.9 billion.
The company's revenues for the trailing twelve months amount to $1.7 billion, highlighting its prominence in the neuropsychiatric therapeutics sector. Alkermes has a diverse portfolio of commercial products and clinical-stage candidates, with a strategic emphasis on treating high-prevalence conditions such as opioid dependence, alcohol use disorder, and schizophrenia.
The company's competitive edge lies in its proprietary drug delivery technologies and its persistent focus on underserved patient populations in mental health and addiction medicine.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
